HostDx Sepsis in Patients With Acute Respiratory Infections
This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected respiratory infections. The primary endpoint of the study is to prospectively validate the HostDx Sepsis test for infections. As a secondary endpoint the correlation of participant prognosis and gene expression results in the HostDx Sepsis test will be validated. Participants presenting to the emergency departments of enrolling sites with a suspected bacterial or viral respiratory infection and 2+ vital signs are meeting enrollment criteria.
This research study is led by Dr. Jay Steingrub.
Contact: Sherell Thornton-Thompson, 413-794-9056
Pulmonary/ Critical Care
Baystate Medical Center, 759 Chestnut St, Springfield, MA
Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample
Patients presenting to the ED with acute respiratory infections
- Age > 18 years
- Suspected Acute upper or lower respiratory infection
- Able to provide informed consent
- Treatment with antibiotics, antiviral agents, or antifungal agents within the past 7 days.
- Prisoners, mentally disabled, or unable or unwilling to give consent.
- Previously enrolled in the present clinical trial.
- Concurrently enrolled in other clinical studies requiring blood draws totaling more than 35 ml within 7 days of enrollment here.
Observational [Patient Registry]